UK Markets close in 4 hrs 22 mins
  • FTSE 100

    7,147.80
    +18.59 (+0.26%)
     
  • FTSE 250

    22,785.10
    +100.26 (+0.44%)
     
  • AIM

    1,191.83
    +3.09 (+0.26%)
     
  • GBP/EUR

    1.1723
    -0.0043 (-0.36%)
     
  • GBP/USD

    1.3263
    -0.0039 (-0.2944%)
     
  • BTC-GBP

    43,047.81
    +431.40 (+1.01%)
     
  • CMC Crypto 200

    1,459.17
    +20.29 (+1.41%)
     
  • S&P 500

    4,577.10
    +64.06 (+1.42%)
     
  • DOW

    34,639.79
    +617.75 (+1.82%)
     
  • CRUDE OIL

    68.26
    +1.76 (+2.65%)
     
  • GOLD FUTURES

    1,769.70
    +9.00 (+0.51%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • HANG SENG

    23,766.69
    -22.24 (-0.09%)
     
  • DAX

    15,286.31
    +23.20 (+0.15%)
     
  • CAC 40

    6,795.44
    -0.31 (-0.00%)
     
Markets:

European stock markets push higher as Omicron strain concerns ease

The Law Offices of Frank R. Cruz Announces Investigation of Novavax, Inc. (NVAX) on Behalf of Investors

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LOS ANGELES, October 25, 2021--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 19, 2021 Politico reported that despite prior representations regarding the Company’s vaccine analytics and testing, two people "with direct knowledge of the matter" claim Novavax "has struggled to attain anywhere close" to the 90 percent vaccine purity levels required to meet Food and Drug Administration guidance. The report continues, "[a]nother person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent."

On this news, Novavax’s share price fell $23.69, or almost 15%, to close at $136.86 per share on October 20, 2021, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Novcavax securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005348/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting